Skip to content

Immunocore

US · IMCR #2968 by market cap Listed 2021
26.41 -0.22 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.0 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.98% -1.96pp
Institutions
153 -6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund48.95%
Hedge Fund47.64%
VC/PE Fund1.83%
Public Company1.17%
Private Company1.01%
Government Pension Fund0.38%
Individual/Insider0.10%
Other2.81%

Top holders as of 2026-06-30

Wellington Management Group 11.07% · 5.72M sh
RTW Investments, LP 9.42% · 4.87M sh
PRIMECAP Management Company 7.04% · 3.64M sh
Bellevue Asset Management AG 5.40% · 2.79M sh
Tang Capital Management, LLC 5.13% · 2.65M sh
Point72 Asset Management, L.P. 4.29% · 2.22M sh
Acadian Asset Management LLC 3.53% · 1.82M sh
Vestal Point Capital, LP 3.48% · 1.80M sh
FMR 3.36% · 1.74M sh
Millennium Management LLC 3.10% · 1.60M sh
Armistice Capital LLC 2.77% · 1.43M sh
Two Sigma Investments, LP 3.19% · 1.65M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 33 buys · 17 sells

NameRoleStake
Bahija Jallal Chief Executive Officer 0.05%
John Bell Independent Non-Executive Chairperson 0.03%
David Berman Former Officer 0.02%
Tina Leger Former Chief Human Resources Officer 0.00%
John Goll SVP, Finance & Chief Accounting Officer 0.00%
Peter Ratcliffe Independent Non-Executive Director 0.00%
Kristine Peterson Independent Non-Executive Director --
Roy Steven Herbst Independent Non-Executive Director --
Brian Di Donato Former Executive VP, CFO & Strategy --
Baker Bros. Advisors LP -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-05-26 John Bell Independent Non-Executive Chairperson Other Derivative Acquisition +27,492 $28.52
2026-05-26 Kristine Peterson Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Roy Steven Herbst Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Peter Ratcliffe Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 William Pao Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Siddharth Kaul Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-03-10 David Berman Former Officer Intent to Sell (Form 144) -11,832 $32.57
2026-02-17 Bahija Jallal Chief Executive Officer Derivative Exercise and Sale -11,474 $32.35
2026-02-17 Bahija Jallal Chief Executive Officer Intent to Sell (Form 144) -11,474 $32.35
2026-02-17 John Goll SVP, Finance & Chief Accounting Officer Derivative Exercise and Sale -698 $32.35
2026-02-17 Tina Leger Former Chief Human Resources Officer Derivative Exercise and Sale -1,000 $32.35
2026-02-17 Tina Leger Former Chief Human Resources Officer Intent to Sell (Form 144) -1,000 $32.35
2026-02-17 David Berman Former Officer Derivative Exercise and Sale -5,965 $32.35
2026-02-17 David Berman Former Officer Intent to Sell (Form 144) -5,965 $32.35
2026-02-16 Bahija Jallal Chief Executive Officer Other Derivative Acquisition +88,573 --
2026-02-16 Bahija Jallal Chief Executive Officer Other Derivative Acquisition +395,066 $32.38
2026-02-16 Bahija Jallal Chief Executive Officer Derivative Exercise and Retained +12,343 --
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Other Derivative Acquisition +7,411 --
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Other Derivative Acquisition +21,252 $32.38
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Derivative Exercise and Retained +653 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Immunocore discussion 0 comments

Add a comment